Drug Profile

KI 3106

Alternative Names: KI-3106

Latest Information Update: 22 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

22 Apr 2025 KI 3106 is still in phase I development in Hyperlipidaemia in South Korea (Kuhnil Pharma pipeline, April 2025)
28 Nov 2024 No recent reports of development identified for phase-I development in Hyperlipidaemia in South Korea
07 Oct 2021 Phase-I clinical trials in Hyperlipidaemia in South Korea (unspecified route) (Kuhnil Pharma pipeline, October 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com